Podcast

All About Bleeding: Transfusion targets after cardiac surgery and intracranial bleeding on warfarin

Subscribe on iTunes

This week: The TITRE2 trial about hemoglobin transfusion strategies after cardiac surgery and the RETRACE study about intracranial bleeding in patients on warfarin.

Nathan and Amol want you to understand the following:

1. In cardiac surgery patients, a restrictive transfusion strategy was no different than liberal transfusion in terms of combined clinical outcomes of infectious and vascular events but may have been associated with increased mortality.

2. In patients on oral anticoagulants with an intracranial bleed, a retrospective study found that reversal of anticoagulation to an INR of < 1.3 within 4 hours and a systolic blood pressure of < 160 mmHg was associated with less extension of bleeding. Re-starting oral anticoagulation after intracranial bleed was associated with fewer ischemic events and no more bleeding. These results are limited by the retrospective design.

Continuing Medical Education

Internists can receive 0.5 hours of Continuing Medical Education credit for each podcast they listen to through the Canadian Society of Internal Medicine (MOC Category 1) and the American Medical Association (PRA Category 1). To receive CME credit for listening to this podcast, please click here to fill out our Evaluation and Impact Assessment Form.

The papers

GJ Murphy et al. Liberal or restrictive transfusion after cardiac surgery. N Engl J Med. 2015 Mar 12;372(11):997-1008. (PubMed).

JB Kuramatsu et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015 Feb 24;313(8):824-36. (PubMed).

Good stuff

Being Mortal. Atul Gawande.

Finding Equilibrium in See-Sawing Libidos. Mark Jaffe. New York Times. 6 Mar 2015.

Leave a Comment

Your email address will not be published. Required fields are marked *

Republish this article

Republish this article on your website under the creative commons licence.

Learn more